文献速递血栓与止血造血干细胞移植与细胞治疗

抗凝策略对造血干细胞移植后血栓复发与出血的影响

Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation.
PubMed 文献 · Am J Hematol · 2021-06-24

该回顾性研究纳入2006-2015年有静脉血栓栓塞症(VTE)史的造血干细胞移植(HCT)患者,按血小板减少时抗凝策略分为继续抗凝组(227例)和暂停抗凝组(113例),发现两组30天内VTE复发风险无显著差异(3% vs 4%,p=0.61),继续抗凝组总体出血风险非显著增高(41% vs 31%,p=0.08);在250例异基因移植亚组中,HIGH-2-LOW评分每增加1分与100天VTE复发显著相关(OR 1.57 [95%CI 1.10-2.23])。

要点

  • 血小板减少时暂停抗凝未显著增加30天内VTE复发风险,但需权衡出血风险。
  • HIGH-2-LOW评分每增1分,异基因移植后100天VTE复发风险增加(OR 1.57)。
  • 血小板植入后恢复抗凝与较低复发风险相关(OR 0.48 [0.20-1.14])。

核心结论

  • 血小板减少时暂停抗凝可能优化风险获益平衡,但造血恢复后仍需策略预防VTE复发。

研究设计与样本

  • 回顾性研究纳入2006-2015年有VTE史的自身及异基因HCT患者,按血小板减少时抗凝策略分组,采用逆概率加权比较30天内VTE复发和出血,并用多因素logistic回归评估100天VTE复发与HIGH-2-LOW评分及恢复抗凝的关系。

主要发现

  • 13%的移植受者有HCT前VTE,符合标准者中227例继续抗凝、113例暂停抗凝。
  • 继续抗凝组与暂停抗凝组30天内VTE复发率分别为3%和4%(p=0.61),差异无统计学意义;总体出血发生率分别为41%和31%(p=0.08),继续抗凝组非显著增高。
  • 在250例异基因HCT亚组中,HIGH-2-LOW评分每增加1分与100天VTE复发显著相关(OR 1.57 [95%CI 1.10-2.23]);血小板植入时恢复抗凝与较低复发风险相关(OR 0.48 [0.20-1.14])。

临床怎么用

  • 对于HCT前有VTE史的患者,在血小板减少期间可考虑暂时暂停抗凝以降低出血风险。
  • 可使用HIGH-2-LOW评分评估异基因HCT后100天VTE复发风险。
  • 血小板植入后应评估恢复抗凝以降低VTE复发风险。

局限性

  • 回顾性研究设计可能引入选择偏倚和混杂因素。
  • 恢复抗凝与VTE复发关联的95%CI宽且跨1,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

History of venous thromboembolism (VTE) is prevalent among patients undergoing hematopoietic cell transplantation (HCT). Management of anticoagulation is particularly challenging as most patients will have chemotherapy-induced thrombocytopenia while awaiting engraftment post-HCT. We conducted a retrospective study of autologous and allogeneic HCT recipients with prior VTE from 2006-2015 to 1) compare anticoagulant strategies on short-term VTE recurrence and bleeding and 2) assess predictors for VTE recurrence beyond 30 days. Patients with VTE were allocated to two cohorts based on anticoagulant strategy at thrombocytopenia onset and underwent inverse probability weighting to assess primary outcomes of VTE recurrence and bleeding within 30 days post-HCT. Subsequently, multivariable logistic regression model was used to assess the association of 100-day VTE recurrence by the HIGH-2-LOW VTE risk assessment score and whether patients resumed anticoagulation at platelet recovery. Thirteen percent of recipients had VTE prior to HCT; of those meeting inclusion criteria, 227 continued anticoagulation and 113 temporarily discontinued it. Anticoagulant strategy was not significantly associated with decreased risk of VTE recurrence within 30 days (3% vs 4%, p = 0.61); however, risk of overall bleeding was non-significantly higher in those who continued vs discontinued anticoagulation (41% vs 31%, p = 0.08). In a subgroup of 250 allogeneic HCT patients, every one-point increase of HIGH-2-LOW score was significantly associated with VTE recurrence at 100 days (OR 1.57 [95% CI 1.10-2.23]), while anticoagulation resumption upon platelet engraftment was associated with lower recurrent risk (OR 0.48 [0.20-1.14]). Temporarily withholding anticoagulation during thrombocytopenia may optimize risk-benefit tradeoffs, though additional strategies are essential to prevent VTE recurrence after hematopoietic recovery.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Martens KL, Amos CI, Hernandez CR, et al. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021. PMID: 34097772. doi:10.1002/ajh.26268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。